Your World, Fully Explored.
Published loading...Updated

Ozempic and Wegovy May Have Landed 25,000 People in the ER—Here's the Scary Reason Why

  • A new study published in Annals of Internal Medicine found that semaglutide-based weight-loss drugs caused about 25,000 emergency room visits in the US from 2022 to 2023 due to adverse effects.
  • Researchers analyzed data from 82 hospitals collected between January 1, 2022, and December 31, 2023, focusing on gastrointestinal complications linked to semaglutide use.
  • Nearly 70 percent of the ER visits involved gastrointestinal issues like gastroparesis, with 15 percent of those visits resulting in hospitalization, while 15.6 percent were due to hypoglycemia.
  • Pieter Cohen, MD, study author, noted semaglutide rarely causes severe hospitalizing events but recommended clinicians counsel patients about GI risks and adjust antidiabetic drugs to reduce hypoglycemia.
  • These findings have prompted calls for stricter regulations enforcing medical oversight and mandatory monitoring before and during weight-loss injection therapy to improve patient safety.
Insights by Ground AI
Does this summary seem wrong?

19 Articles

All
Left
1
Center
3
Right
6
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 60% of the sources lean Right
60% Right
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Independent Español broke the news in on Friday, May 2, 2025.
Sources are mostly out of (0)